CONTINUOUSLY INFUSED INTRATHECAL BACLOFEN FOR SPASTIC/DYSTONIC HEMIPLEGIA
- 1 May 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 78 (3) , 247-254
- https://doi.org/10.1097/00002060-199905000-00012
Abstract
The objective of this study was to determine whether the continuous intrathecal delivery of baclofen will control spastic hypertonia associated with long-standing hemiplegia from acquired brain injury. Six hemiparetic patients (average age, 50 (range, 42-66) yr) with more than 6 mo of disabling lower limb spastic hypertonia on one side caused by either a unilateral traumatic brain injury or a stroke were recruited in a consecutive manner. The setting was a tertiary care outpatient and inpatient rehabilitation center directly attached to a university hospital. Patients were screened via a randomized, double-blind, placebo-controlled, crossover design to receive either an intrathecally administered bolus injection of normal saline or 50 μg of baclofen. Data for Ashworth rigidity scores, spasm scores, and deep tendon reflex scores were collected on the affected upper limb and lower limb side. Those who dropped an average of two points on their affected lower limb side Ashworth scores were then offered computer-controlled pump implantation for continuous intrathecal administration of baclofen. Differences over time were assessed via descriptive statistics and Wilcoxon's signed-rank test. After 3 mo of treatment, the average lower limb Ashworth score on the affected side decreased from 3.7 ± 1.0 to 1.9 ± 0.6 standard deviation (SD) (P < 0.0001), the reflex score from 1.8 ± 1.3 to 0.5 ± 0.8 SD (P = 0.0208), and the spasm score from 1.3 ± 1.2 to 0.8 ± 1.3 SD (P > 0.05). The average upper limb Ashworth score on the affected side decreased from 3.4 ± 0.9 to 2.1 ± 0.9 SD (P = 0.0002), the reflex score from 2.3 ± 0.5 to 1.7 ± 0.5 SD (P > 0.050, and the spasm score from 0.8 ± 1.3 to 0 ± 0 SD (P > 0.05). The average intrathecally administered dose of baclofen that was required to attain these effects was 205.3 μg, which was continuously infused for 24 h. Continuous intrathecal infusion of baclofen is capable of maintaining a reduction in the dystonia on the hemiparetic side without significantly affecting motor strength on the normal side.Keywords
This publication has 16 references indexed in Scilit:
- Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary reportJournal of Neurosurgery, 1997
- Intrathecal Baclofen for Spastic Hypertonia in Brain InjuryJournal of Head Trauma Rehabilitation, 1997
- Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter studyJournal of Neurosurgery, 1993
- CONTINUOUS INTRATHECAL BACLOFEN IN SPINAL CORD SPASTICITYAmerican Journal of Physical Medicine & Rehabilitation, 1992
- Intrathecal baclofen and the H-reflex.Journal of Neurology, Neurosurgery & Psychiatry, 1989
- Intrathecal Baclofen for Severe Spinal SpasticityNew England Journal of Medicine, 1989
- ContracturesPublished by Wolters Kluwer Health ,1987
- Studies in the Primate on the Analgetic Effects Associated with Intrathecal Actions of Opiates,α-Adrenergic Agonists and BaclofenAnesthesiology, 1981
- Selenium: A Case for Its Essentiality in ManNew England Journal of Medicine, 1981
- Segmental reflex pathways in spinal shock and spinal spasticity in manJournal of Neurology, Neurosurgery & Psychiatry, 1974